SCHEMBL6501460

SCHEMBL6501460

CCOC(=O)c1cccc(N(C)Cc2cc(C)c3nc(C)n(Cc4ccc(Cl)cc4Cl)c3c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PPARG P37231 1/20 0.38
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PPARA Q07869 1/20 0.35
TP53 P04637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ELANE P08246 2/20 0.35
DCTPP1 Q9H773 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488659 0.90 PPARA (0.43) LMNASMN1; SMN2PPARGCYP3A4CYP2C9
SCHEMBL6487974 0.83 MAPT (0.42) LMNASMN1; SMN2PPARGKDM4EALDH1A1
SCHEMBL6488419 0.82 LMNA (0.49) LMNASMN1; SMN2PPARGKDM4EALDH1A1
SCHEMBL6490180 0.79 LMNA (0.41) LMNASMN1; SMN2PPARGKDM4EALDH1A1
SCHEMBL6500747 0.78 PIK3C2B (0.40) LMNASMN1; SMN2PPARGCYP3A4CYP2C9
SCHEMBL6489915 0.76 NR4A2 (0.46) LMNASMN1; SMN2PPARGMAPTMAPK1
SCHEMBL6490261 0.75 CYP1A2 (0.42) LMNASMN1; SMN2CYP1A2RAB9A
SCHEMBL6168359 0.75 LMNA (0.54) LMNASMN1; SMN2PPARGKDM4EALDH1A1
SCHEMBL6501562 0.74 NR4A2 (0.57) PPARGNPC1RAB9A
SCHEMBL6490602 0.74 PPARG (0.41) LMNASMN1; SMN2PPARGCYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD LMNA 3711/4885SMN1; SMN2 1128/4885PPARG 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.